Résumé
Objective To study the clinical value of procalcitonon (PCT) for predicting development of acute kidney injury and outcomes in patients with acute pancreatitis (AP). Methods 205 inpatients with acute pancreatitis in our hospital were enrolled in our study during January 2012 to March 2013. According to acute kidney injury (AKI) occurred in three consecutive days or not, the patients were divided into AKI group (n = 32) and control group (n=173). Crea, Urea, CysC and PCT, serum amyloid A (SAA), interleukin-6 (IL-6) and C reactive protein (CRP) were analyzed. The predictive validity of these indicators was constructed by receiver operating characteristics (ROC) curve. Results PCT, IL-6, and CRP level of AKI group showed significant higher in AKI group than control group (P0.05). The AUC value of PCT showed significant higher than the AUC value of CRP, IL-6 and SAA(P<0.05). Conclusion PCT is a early, sensitive, specific biomarker for predicting AKI of patients with AP.